Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.

Blockhead10-16

Hims stock has rallied almost 22% this week on enthusiasm after the Food and Drug Administration said it will allow compounded versions of Eli Lilly's (LLY) blockbuster weight-loss drug. ↑ X ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475999444?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/10/Stock-Hims-pills-company-150x150.jpg","is_english":true,"pubTime":"2024-10-16 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475999444","market":"nz","top_or_hot":-1,"title":"Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.","media":"Blockhead","content":"<div>\n<p>Hims stock has rallied almost 22% this week on enthusiasm after the Food and Drug Administration said it will allow compounded versions of Eli Lilly's (LLY) blockbuster weight-loss drug.\n\n\n\n↑\nX\n\n\n\n\n...</p>\n\n<a href=\"https://www.investors.com/news/technology/hims-stock-rally-tirzepatide-semaglutide-fda/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/hims-stock-rally-tirzepatide-semaglutide-fda/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims stock has rallied almost 22% this week on enthusiasm after the Food and Drug Administration said it will allow compounded versions of Eli Lilly's (LLY) blockbuster weight-loss drug.\n\n\n\n↑\nX\n\n\n\n\n...</p>\n\n<a href=\"https://www.investors.com/news/technology/hims-stock-rally-tirzepatide-semaglutide-fda/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1069344957.HKD","symbol_name":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","start_time":0,"source_url":"https://www.investors.com/news/technology/hims-stock-rally-tirzepatide-semaglutide-fda/","article_id":"2475999444","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/10/Stock-Hims-pills-company-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475999444","pubTimestamp":1729080051,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4581":"高盛持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","NVO.AU":"NOVO RESOURCES CORP-CDI","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","BK4588":"碎股","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4532":"文艺复兴科技持仓","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","BK4534":"瑞士信贷持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","HIMS":"Hims & Hers Health Inc.","LLY":"礼来","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK7104":"黄金"},"translate_title":"Hims&Hers股价本周上涨了22%。为什么这一举措现在面临风险。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO.AU":1,"NVO":1,"HIMS":1,"LLY":0.7},"content_text":"Hims stock has rallied almost 22% this week on enthusiasm after the Food and Drug Administration said it will allow compounded versions of Eli Lilly's (LLY) blockbuster weight-loss drug.\n\n\n\n↑\nX\n\n\n\n\nHow Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors\n\n\n\n\nSpecifically, the FDA said compounding pharmacies and facilities will be allowed to sell their versions of tirzepatide. Lilly sells tirzepatide as a type 2 diabetes treatment called Mounjaro and as the obesity treatment Zepbound. The FDA is currently reexamining whether tirzepatide is in short supply. If so, compounders can step in to help alleviate the shortage.\nHims & Hers Health (HIMS) shares jumped 9.7% on Monday and 11.2% on Tuesday following the FDA's decision.\nBut the massive jump in Hims stock might be at risk, based on IBD stock research.\nAccording to MarketSurge, Hims stock has an average true range of 1.14. That means on any given day shares travel an average 1.14 above or below their opening price — or 5.5%.\nBut investors are encouraged to have a stop loss at 7% to 8%. So, the entry must be perfect with Hims stock or they'll get shaken out with the normal 5.5% movement.\nHims Stock Is Nearing A Breakout\nMeanwhile, Hims stock is forming a cup base with a buy point at 25.74. Shares approached that mark on Tuesday.\nShares this week have cleared a short-term high of 19.99 and a trendline, offering early entries.\nHIMS is approaching a 25.74 buy point. But, at 22.80, it's actually trading 11% below that high. A handle could also form on the base. Usually, a handle can form anywhere from less than 1% off the cup's left-side peak and up to usually 15%.\nBut it's anyone's guess how the FDA move will play out. An industry group for compounders called the Outsourcing Facilities Association sued the FDA after the agency removed tirzepatide from its drug shortages list. When a drug is on the shortages list, compounders can step in to help fill the gap.\nAccording to the Outsourcing Facilities Association, tirzepatide is, indeed, in shortage.\nIn response to the lawsuit, the FDA said it would review its decision and allow compounders to make their versions of tirzepatide in the meantime. Hims stock took off on the news.\nHims Focuses On Semaglutide\nBut, it's important to note, Hims & Hers doesn't make tirzepatide. Instead, the company compounds its version of semaglutide injections, which Novo Nordisk (NVO) sells in diabetes and obesity treatment as Ozempic and Wegovy, respectively.\n\"Whenever we bring a treatment to our platform, our first consideration is how accessible it will be for the large majority of customers and accessible means consistently available at a reasonable price,\" a spokesperson told Investor's Business Daily by email. \"Through that lens, right now we're focused on offering semaglutide and our oral therapies.\"\nHims & Hers is due to report its third-quarter earnings after the market closes on Nov. 4. Hims stock analysts project adjusted earnings of 10 cents per share on $382 million in sales, according to FactSet. Earnings would reverse from a year-ago loss, while sales rocket 68%.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nTop 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record\nWhy Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade\nIBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks\nLooking For The Next Big Stock Market Winners? Start With These 3 Steps\nGet Timely Buy & Sell Alerts With IBD Leaderboard","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475999444"}